We found that in humans, LCN2 is elevated in AD patient brains parallel to the prevalence of the neuritic plaques, suggesting a relationship between reduced neurogenic capacity and the etiology of these diseases, which needs to be further addressed. This evidence concerns the gene LCN2 and Alzheimer disease.